|
1
|
Louie AV, van Werkhoven E, Chen H, Smit
EF, Paul MA, Widder J, Groen HJ, van den Borne BE, De Jaeger K,
Slotman BJ, et al: Patient reported outcomes following stereotactic
ablative radiotherapy or surgery for stage IA non-small-cell lung
cancer: Results from the ROSEL multicenter randomized trial.
Radiother Oncol. 117:44–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aisner J, Manola JB, Dakhil SR, Stella PJ,
Sovak MA and Schiller JH: Vandetanib plus chemotherapy for
induction followed by vandetanib or placebo as maintenance for
patients with advanced non-small-cell lung cancer: A randomized
phase 2 PrECOG study (PrE0501). J Thorac Oncol. 8:1075–1083. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lal R, Bourayou N, Hillerdal G, Nicolson
M, Vikstrom A, Lorenzo M, D'yachkova Y, Barriga S and Visseren-Grul
C: Home administration of maintenance pemetrexed for patients with
advanced non-squamous non-small cell lung cancer: Rationale,
practicalities and phase II feasibility study design. Health Qual
Life Outcomes. 11:1632013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Z, Liu W, Gillin M, Gomez DR, Komaki
R, Cox JD, Mohan R and Chang JY: Assessing the robustness of
passive scattering proton therapy with regard to local recurrence
in stage III non-small cell lung cancer: A secondary analysis of a
phase II trial. Radiat Oncol. 9:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graff JR, Boghaert ER, De Benedetti A,
Tudor DL, Zimmer CC, Chan SK and Zimmer SG: Reduction of
translation initiation factor 4E decreases the malignancy of
ras-transformed cloned rat embryo fibroblasts. Int J Cancer.
60:255–263. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenwald IB, Hutzler MJ, Wang S, Savas L
and Fraire AE: Expression of eukaryotic translation initiation
factors 4E and 2alpha is increased frequently in bronchioloalveolar
but not in squamous cell carcinomas of the lung. Cancer.
92:2164–2171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaufman JL, Glockner F, Chang BB, Koslow
AR, Shah DM and Leather RP: Impact of the presence of orthopedic
hardware on technical performance of major amputations. Ann Vasc
Surg. 4:356–358. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang SH, Kim JE, Lee JH, Minai-Tehrani A,
Han K, Chae C, Cho YH, Yun JH, Park K, Kim YS, et al: Aerosol
delivery of eukaryotic translation initiation factor 4E-binding
protein 1 effectively suppresses lung tumorigenesis in K-rasLA1
mice. Cancer Gene Ther. 20:331–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zagryazhskaya A and Zhivotovsky B: miRNAs
in lung cancer: A link to aging. Ageing Res Rev. 17:54–67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamashita R, Sato M, Kakumu T, Hase T,
Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth
inhibitory effects of miR-221 and miR-222 in non-small cell lung
cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF
and Zhang XY: miR-138 inhibits proliferation by targeting
3-phosphoinositide-dependent protein kinase-1 in non-small cell
lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan
S, Cai H, Luo Q, Lv Z, et al: miR-194 inhibits the proliferation,
invasion, migration, and enhances the chemosensitivity of non-small
cell lung cancer cells by targeting forkhead box A1 protein.
Oncotarget. 7:13139–13152. 2016.PubMed/NCBI
|
|
13
|
Komiyama K, Kobayashi K, Minezaki S,
Kotajima F, Sutani A, Kasai T, Mori K, Hoshi E, Takayanagi N,
Koyama S, et al: Kanto Respiratory Disease Study Group: Phase I/II
trial of a biweekly combination of S-1 plus docetaxel in patients
with previously treated non-small cell lung cancer (KRSG-0601). Br
J Cancer. 107:1474–1480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Wu S, Ou G, Bi N, Li W, Ren H, Cao
J, Liang J, Li J, Zhou Z, et al: Randomized phase II study of
concurrent cisplatin/etoposide or paclitaxel/carboplatin and
thoracic radiotherapy in patients with stage III non-small cell
lung cancer. Lung Cancer. 77:89–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shukuya T, Ko R, Mori K, Kato M, Yagishita
S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, et al:
Prognostic factors in non-small cell lung cancer patients who are
recommended to receive single-agent chemotherapy (docetaxel or
pemetrexed) as a second- or third-line chemotherapy: In the era of
oncogenic drivers and molecular-targeted agents. Cancer Chemother
Pharmacol. 76:771–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Satheesha S, Cookson VJ, Coleman LJ,
Ingram N, Madhok B, Hanby AM, Suleman CA, Sabine VS, Macaskill EJ,
Bartlett JM, et al: Response to mTOR inhibition: Activity of eIF4E
predicts sensitivity in cell lines and acquired changes in eIF4E
regulation in breast cancer. Mol Cancer. 10:192011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizutani R, Imamachi N, Suzuki Y, Yoshida
H, Tochigi N, Oonishi T, Suzuki Y and Akimitsu N: Oncofetal protein
IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E
through the destabilization of EIF4E-BP2 mRNA. Oncogene.
35:3495–3502. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robichaud N, del Rincon SV, Huor B, Alain
T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH,
Furic L, et al: Phosphorylation of eIF4E promotes EMT and
metastasis via translational control of SNAIL and MMP-3. Oncogene.
34:2032–2042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015.PubMed/NCBI
|
|
20
|
Smith KA, Zhou B, Avdulov S, Benyumov A,
Peterson M, Liu Y, Okon A, Hergert P, Braziunas J, Wagner CR, et
al: Transforming growth factor-β1 induced epithelial mesenchymal
transition is blocked by a chemical antagonist of translation
factor eIF4E. Sci Rep. 5:182332015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Inglis DJ, Lavranos TC, Beaumont DM, Leske
AF, Brown CK, Hall AJ and Kremmidiotis G: The vascular disrupting
agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors
in renal and breast cancer. Cancer Biol Ther. 15:1552–1560. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tejero R, Navarro A, Campayo M, Viñolas N,
Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L,
Ramirez J, et al: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J, Huang Y, Gao Y, Wu H, Dong W and Liu
L: Antibiotic drug rifabutin is effective against lung cancer cells
by targeting the eIF4E-β-catenin axis. Biochem Biophys Res Commun.
472:299–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Zhang L, Liu D, Cheng Y, Jing YT, Yu
H, Zhou P, Song J and Li WM: Overexpression of eukaryotic
translation initiation factor 4E-binding protein 1 induces the
alteration of immune status in H1299 lung cancer cells. Thorac
Cancer. 6:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li S, Jia Y, Jacobson B, McCauley J,
Kratzke R, Bitterman PB and Wagner CR: Treatment of breast and lung
cancer cells with a N-7 benzyl guanosine monophosphate tryptamine
phosphoramidate pronucleotide (4Ei-1) results in chemosensitization
to gemcitabine and induced eIF4E proteasomal degradation. Mol
Pharm. 10:523–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Deng T, Li X, Liu H, Zhou H, Ma
J, Wu M, Zhou M, Shen S, Li X, et al: microRNA-141 is involved in a
nasopharyngeal carcinoma-related genes network. Carcinogenesis.
31:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang H, Zhao PJ, Su D, Feng J and Ma SL:
Paris saponin I induces apoptosis via increasing the Bax/Bcl-2
ratio and caspase-3 expression in gefitinib-resistant non-small
cell lung cancer in vitro and in vivo. Mol Med Rep. 9:2265–2272.
2014.PubMed/NCBI
|
|
28
|
Lee SH, Kim DY, Jing F, Kim H, Yun CO, Han
DJ and Choi EY: Del-1 overexpression potentiates lung cancer cell
proliferation and invasion. Biochem Biophys Res Commun. 468:92–98.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
You BR, Shin HR and Park WH: PX-12
inhibits the growth of A549 lung cancer cells via G2/M phase arrest
and ROS-dependent apoptosis. Int J Oncol. 44:301–308.
2014.PubMed/NCBI
|
